FDA OKs Octreotide Capsules; COVID-19 Damages Endocrine System

FDA OKs Octreotide Capsules; COVID-19 Damages Endocrine System

The FDA accepted octreotide (Mycapssa) capsules for lengthy-interval of time upkeep of acromegaly in those already handled with octreotide or lanreotide, Chiasma announced. Decided remedy and scientific devices may perhaps perhaps presumably merely inadvertently repeat patients to defective endocrine-disrupting chemicals,…